Topoisomerases I and II are involved in virtually all DNA transactions and are the targets of clinically effective anti-cancer and anti-infective drugs (1, 2). Topoisomerases exploit a tyrosine nucleophile to attack the phosphodiester backbone, yielding a covalent enzyme-DNA adduct on one side of the resulting break that permits the passage of strand(s) through the break. Type I enzymes operate by cleaving one DNA strand and passing another strand through the nick; type II enzymes cleave both DNA strands and allow passage of a duplex segment through the double strand break. Closure of the break by reversal of the cleavage step results in a change to the topology of DNA, with no net effect on its chemical structure.Type I topoisomerases are subclassified as type IA or type IB enzymes, depending on whether they form a 5Ј-or 3Ј-phosphotyrosyl adduct, respectively. Type IA enzymes are distributed widely in the bacterial, archaeal, and eukaryal domains of life. Type IB enzymes are found in eukarya, eukaryotic viruses (poxviruses and mimivirus), and many genera of bacteria (1-6). Eukaryotic nuclear type IB enzymes are large monomeric polypeptides, typically Ͼ90 kDa, whereas the viral and bacterial type IB polypeptides are much smaller, typically ϳ33-36 kDa. Despite their differences in size, the poxvirus and nuclear type IB enzymes have a common core tertiary structure and catalytic mechanism (7,8), which is shared with the tyrosine recombinase family (9 -12), thereby suggesting a common ancestry for type IB topoisomerases and tyrosine recombinases (7,8). The active sites of poxvirus and nuclear type IB topoisomerases consist of five conserved functional groups, e.g. Arg-130, Lys-167, Arg-220, His-265, and Tyr-274 in vaccinia virus topoisomerase IB (vaccinia TopIB), which execute the cleavage and religation transesterification steps of the catalytic cycle (13-21).Vaccinia TopIB is composed of two domains separated by a flexible protease-sensitive linker (22, 23). The 234-aa 3 carboxyl-terminal (C) domain contains the active site and catalyzes DNA transesterification and supercoil relaxation but has reduced affinity for DNA compared with the full-length enzyme (24). The 80-aa amino-terminal (N) domain interacts with DNA in the major groove (22,25,26). The atomic structures of the individual domains of vaccinia TopIB have been determined by x-ray crystallography (7,22). Whereas the fold and active site of the predominantly ␣-helical catalytic domain are conserved in nuclear type IB topoisomerases (nuclear TopIB) and the tyrosine recombinases (7), the amino-terminal domain, which consists primarily of -strands (22), has no counterpart in tyrosine recombinases, although it is structurally homologous to part of the much larger amino-terminal domain of nuclear TopIB (27).Bacterial type IB topoisomerases were discovered recently (5) and are similar to poxvirus type IB topoisomerases with respect to their size, primary structures, and domain organization (Fig. 1). Mutational analyses indicate that the transesterification mec...